Efalizumab: A Review of its Use in the Management of Chronic Moderate-to-Severe Plaque Psoriasis

By Frampton James E.   Plosker Greg L.  

American Journal of Clinical Dermatology, Vol. 10, Iss. 1, 2009-01 ,pp. : 51-72

Adis International

Access to resources Recommend Favorite

Efficacy and Safety of the Betamethasone Valerate 0.1% Plaster in Mild-to-Moderate Chronic Plaque Psoriasis: A Randomized, Parallel-Group, Active-Controlled, Phase III Study

By Naldi Luigi  

American Journal of Clinical Dermatology, Vol. 12, Iss. 3, 2011-06 ,pp. : 191-201

Adis International

Access to resources Recommend Favorite

Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities: Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

By Kimball Alexa B.  

American Journal of Clinical Dermatology, Vol. 12, Iss. 1, 2011-02 ,pp. : 51-62

Adis International

Access to resources Recommend Favorite

Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: An open-label, 12- to 36-month continuation study

By Edward Hogan R.   Garnett W.R.   Thadani V.M.   Carbatrol Study Group  

Clinical Therapeutics, Vol. 25, Iss. 10, 2003-10 ,pp. : 2586-2596

Elsevier

Access to resources Recommend Favorite

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis: A Comprehensive Analysis of All Adalimumab Exposure in All Clinical Trials

By Leonardi Craig  

American Journal of Clinical Dermatology, Vol. 12, Iss. 5, 2011-10 ,pp. : 321-337

Adis International

Access to resources Recommend Favorite